BullFrog AI Secures 180-Day Nasdaq Extension and Readies Reverse Split to Regain Compliance
BFRG sits 34% above its 52-week low of $0.425.
Summary
BullFrog AI received a second 180-day Nasdaq compliance period and plans a reverse stock split if needed to lift its share price above $1.00.
Key Events · Legal and Risk Events · BFRG
-
Second Compliance Period Granted
Nasdaq extended the deadline to February 8, 2027, giving the company another 180 days to regain the $1.00 minimum bid price.
-
Reverse Split Contingency
The company notified Nasdaq that it will effect a reverse stock split (ratio 1:2 to 1:15) if the price doesn't recover organically, using stockholder approval from October 2025.
-
Delisting Risk Remains
If compliance is not regained by February 8, 2027, securities will be subject to delisting, though the company can appeal to a Nasdaq Hearings Panel.
-
Going Concern Backdrop
The extension comes days after the Q2 10-Q disclosed a going concern warning and limited financing capacity, heightening the stakes of maintaining the listing.
Analysis · BFRG · Life Sciences
Nasdaq has granted BullFrog AI a second 180-day compliance period, extending the deadline to February 8, 2027, after the stock failed to regain the $1.00 minimum bid price. The company has informed Nasdaq that it will pursue a reverse stock split if the price does not recover organically, relying on stockholder approval from October 2025 for a ratio between 1:2 and 1:15. This move is a critical survival step for a company already facing a going concern warning and limited financing capacity.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.7% of the 1075 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.60%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BFRG was trading at $0.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.6M. The 52-week trading range was $0.43 to $2.04. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.